New and Emerging Therapies for Steatohepatitis and Steatotic Hepatic Disease
ACPE Activity Number:0204-0000-25-049-H01-P Release Date:04/24/2025 Expiration Date:04/24/2028 Activity Type: Knowledge-based CE Credits: 1 contact hour, no partial credit Activity Fee: Member – Free / Non-Member – Not Available
Activity Overview
This presentation will introduce new nomenclature for fatty liver disease as outlined by the American Association for the Study of Liver Disease (AASLD). Management strategies for this condition will be reviewed including the new therapy, resmetirom, which is FDA-approved to treat adults with metabolic-dysfunction-associated steatohepatitis (MASH) who have moderate to advanced liver fibrosis. MASH is an important cause of hepatic dysfunction, which is increasing in prevalence as metabolic risk factors increase in the American population.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
This activity was planned to meet the educational needs of pharmacists and pharmacy technicians who may care for patients diagnosed with fatty liver disease.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.
